Ocugen (OCGN) came into limelight after the company signed a deal to market Bharat Biotech's COVID-19 vaccine (Covaxin) in the United States. OCGN stock has skyrocketed by 144.6% year-to-date. However, after touching highs of $18.77, the stock has corrected below $10. (See Ocugen stock charts on TipRanks) I am bearish on Ocugen considering the factors discussed below. Mixed News for Ocugen The initial surge in Ocugen stock was backed by the positive news of Bharat Biotech partnering with the company. However, Ocugen had a setback when the U.S. Food and Drug Administration rejected the company’s filing for emergency use authorization of the COVID-19 vaccine.
https://www.tipranks.com/news/article/ocugen-stock-seems-unattractive-with-limited-market-opportunity?utm_source=advfn.com&utm_medium=referral
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Ocugen Charts.
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Ocugen Charts.